CancerNetwork
Karmanos Cancer Institute experts in multiple myeloma and chronic myeloid leukemia (CML) took part in a face-off against Cleveland Clinic. Andrew Kin, M.D., hematologist and medical oncologist, and member of the Bone Marrow and Stem Cell Transplant, Hematology Oncology and Multiple Myeloma and Amyloidosis Multidisciplinary Teams (MDTs), was the team captain for Karmanos. He was joined by Craig Cole, M.D., hematologist, member of the Hematology Oncology and Multiple Myeloma and Amyloidosis MDTs; Charles A. Schiffer, M.D., professor emeritus at Wayne State University School of Medicine; Jay Yang, M.D., hematologist and medical oncologist, leader of the Hematology Oncology MDT; and Jeffrey Zonder, M.D., hematologist, leader of the Multiple Myeloma and Amyloidosis MDT and member of the Hematology Oncology MDT.
Both teams debated and discussed new data surrounding the treatment of CML. The debate is broken up into multiple episodes, including:
- Team Introductions: CML Experts from Karmanos Cancer Institute and Cleveland Clinic
- Ponatinib Dose-Ranging Data in Chronic-Phase CML
- Treatment Considerations for Ponatinib in Patients with CML
- Olverembatinib in Patients with Pretreated/Refractory CML
- Potential Role of Olverembatinib in CML
- ASCEMBL: Recent Data Updates for Asciminib in CML
- Clinical Applications for Asciminib in CML
- OPTIC Trial: 3-Year Data Update in CML
- Treatment Updates and Key Highlights in Multiple Myeloma and CML
Watch all episodes here.